000			01568 a2200397 4500
005			20250515023350.0
264		0	_c20061205
008			200612s 0 0 eng d
022			_a0090-8258
024	7		_a10.1016/j.ygyno.2006.03.014 _2doi
040			_aNLM _beng _cNLM
100	1		_aBookman, Michael A
245	0	0	_aSequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. _h[electronic resource]
260			_bGynecologic oncology _cNov 2006
300			_a473-8 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage
650	0	4	_aCarboplatin _xadministration & dosage
650	0	4	_aCohort Studies
650	0	4	_aDrug Administration Schedule
650	0	4	_aEpithelial Cells _xpathology
650	0	4	_aFemale
650	0	4	_aHematologic Diseases _xchemically induced
650	0	4	_aHumans
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasm Staging
650	0	4	_aOvarian Neoplasms _xblood
650	0	4	_aTopotecan _xadministration & dosage
700	1		_aMcMeekin, D Scott
700	1		_aFracasso, Paula M
773	0		_tGynecologic oncology _gvol. 103 _gno. 2 _gp. 473-8
856	4	0	_uhttps://doi.org/10.1016/j.ygyno.2006.03.014 _zAvailable from publisher's website
999			_c16235032 _d16235032